Everest Medicines to offer primary IgAN treatment in South Korea

Everest Medicines, a late clinical-stage biopharmaceutical company that focuses on developing and commercializing pharmaceutical products in the APAC region, recently announced entering into a licensing agreement with Calliditas Therapeutics AB, a clinical-stage biopharmaceutical company that focuses on recognizing, developing and commercializing innovative treatments in orphan indications.

Under this agreement, both the firms will be developing and commercializing NEFECON for treating primary IgA nephropathy (IgAN) in South Korea, enlarging its license in addition to rights held in Singapore and Greater China.

The agreement indicates the latest efforts of the firm to strengthen its commercial footprint further globally.

Kerry Blanchard, MD, Ph.D., CEO of Everest Medicines, said that the firm is excited to fortify its partnership with Calliditas by extending the license agreement for including South Korea and working towards the mutual goal of developing and commercializing NEFECON as a latent novel therapy for treating IgAN globally.

IgAN is more common in Asia as compared to anywhere else globally. But unfortunately, there are no well-known treatments for patients suffering from chronic conditions, emphasizing the substantial and vital unmet need for advanced medicines.

Kevin Yong Guo, Chief Commercial Officer of Everest Medicines, said that South Korea is the third-largest market for pharmaceuticals after China and Japan in the Asia Pacific region and offers incredible opportunities.

The country’s erudite healthcare model aids innovative medicines like NEFECON to have a higher potential healthcare coverage once permitted.

The firm is looking forward to working closely with all the contributing parties and bringing NEFECON to patients suffering from IgAN in South Korea as soon as possible.

Furthermore, Everest Medicines, in the coming months, will be collaborating with South Korea's Ministry of Food and Drug Safety for preparing regulatory filings and an NDA (New Drug Application) for treating IgAN.

Source Credit - https://www.prnewswire.com/news-releases/everest-medicines-enters-into-agreement-with-calliditas-therapeutics-expanding-territory-license-to-develop-and-commercialize-nefecon-in-south-korea-301501428.html